Prognosis of METTL-14 in Endometrial Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorAssiut University
About this trial
1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Hystrectomy operation
Available full clinical data about patient (age, complaint, findings in clinical examination).
Full data about previous biopsy and radiology.
Full data about patient survival, disease progression and history of chemotherapy for three years.
Disqualifiers
1. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.
Trial population
endometrial carcinoma
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Observation
Other interventionobservation of METTL-14 prognosis
IHC
BehavioralIHC of METTL-14
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: endometrial carcinoma2 interventions
Trial outcomes
Primary outcomes
1
Evaluation of immunohistochemical Expression of METTL14 in Type 1 Endometrial Carcinoma
Measurement: Percentage of positive METTL14-stained tumor cells using immunohistochemistry (IHC). Unit: Percentage (%). Time Frame: Baseline.
Time frame
baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: